Page 193 - Read Online

Costa et al. Hepatoma Res 2018;4:35 I http://dx.doi.org/10.20517/2394-5079.2018.06 Page 11 of 11

Fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma: correlation with glucose transporters and p53 expression. J Clin Exp
Hepatol 2015;5:183-9.
23. Lee SD, Kim SH, Kim YK, Kim C, Kim SK, Han SS, Park SJ. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver
transplantation for hepatocellular carcinoma. Transpl Int 2013;26:50-60.
24. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC
clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
25. Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: approaching personalized care. J Hepatol 2015;62:S144-56.
26. Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Kawaratani H, Nishimura N, Fukui H. Combination of
sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. J
Gastroenterol 2014;49:1421-9.
27. Edginton AN, Zimmerman EI, Vasilyeva A, Baker SD, Panetta JC. Sorafenib metabolism, transport, and enterohepatic recycling:
physiologically based modeling and simulation in mice. Cancer Chemother Pharmacol 2016;77:1039-52.
28. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak
S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail
PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
29. Stefano JT, Pereira IV, Torres MM, Bida PM, Coelho AM, Xerfan MP, Cogliati B, Barbeiro DF, Mazo DF, Kubrusly MS, D’Albuquerque
LA, Souza HP, Carrilho FJ, Oliveira CP. Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model. Br J
Med Biol Res 2015;48:408-14.
30. Yang YY, Liu RS, Lee PC, Yeh YC, Huang YT, Lee WP, Lee KC, Hsieh YC, Lee FY, Tan TW, Lin HC. Anti-VEGFR agents ameliorate
hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat. Liver Int
2014;34:521-34.
31. Carvalho CF, Chammas MC, Souza de Oliveira CPM, Cogliati B, Carrilho FJ, Cerri GG. Elastography and contrast-enhanced
ultrasonography in the early detection of hepatocellular carcinoma in an experimental model of nonalcoholic steatohepatitis. J Clin Exp
Hepatol 2013;3:96-101.
32. Rapisarda E, Bettinardi V, Thielemans K, Gilardi MC. Image-based point spread function implementation in a fully 3D OSEM reconstruction
algorithm for PET. Phys Med Biol 2010;55:4131-51.
33. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh
M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring
system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
34. Thoolen B, Maronpot RR, Harada T, Nyska A, Rousseaux C, Nolte T, Malarkey DE, Kaufmann W, Küttler K, Deschl U, Nakae D, Gregson
R, Vinlove MP, Brix AE, Singh B, Belpoggi F, Ward JM. Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary
system. Toxicol Pathol 2010;38:S5-81.
35. Schlageter M, Terracciano LM, D’Angelo S, Sorrentino P. Histopathology of hepatocellular carcinoma. World J Gastroenterol 2014;
20:15955-64.
36. Mattina J, MacKinnon N, Henderson VC, Fergusson D, Kimmelman J. Design and reporting of targeted anticancer preclinical studies: a
meta-analysis of animal studies investigating sorafenib antitumor efficacy. Cancer Res 2016;76:4627-36.
37. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26.
38. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici
M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300.
39. Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ.
Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? PLoS One
2014;9:e105679.